Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Bibliographic Details
Main Authors:	Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1113289/full

Similar Items

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
by: Sha-Sha Wang, et al.
Published: (2022-09-01)

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
by: Tongyi Zhang, et al.
Published: (2023-04-01)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
by: Margherita Nannini, et al.
Published: (2022-12-01)

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
by: Li An, et al.
Published: (2022-12-01)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
by: Qin H, et al.
Published: (2023-07-01)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
by: Paolo D. d'Arienzo, MD, MRCP, et al.
Published: (2023-12-01)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
by: Zichen Zhao, MD, et al.
Published: (2022-06-01)

RET Inhibitors in Non-Small-Cell Lung Cancer
by: Priscilla Cascetta, et al.
Published: (2021-09-01)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
by: Ning Zhou, et al.
Published: (2022-02-01)

Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
by: Ying Wu, et al.
Published: (2022-12-01)

Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01)

Precious Gene: The Application of RET-Altered Inhibitors
by: Qitao Gou, et al.
Published: (2022-12-01)

Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report
by: Loek A.W. De Jong, et al.
Published: (2023-12-01)

Non-small-cell lung cancer: how to manage RET-positive disease
by: Elisa Andrini, et al.
Published: (2022-07-01)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
by: Tomasz Kucharczyk, et al.
Published: (2022-10-01)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-06-01)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
by: Badi El Osta, MD, et al.
Published: (2020-09-01)

<i>RET</i>-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
by: Antoine Desilets, et al.
Published: (2023-08-01)

Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
by: Sara Fancelli, et al.
Published: (2021-03-01)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
by: Misako Nagasaka, et al.
Published: (2023-10-01)

Approximation algorithm for rearrangement distances considering repeated genes and intergenic regions
by: Gabriel Siqueira, et al.
Published: (2021-10-01)

Sequence analysis of the rDNA intergenic spacer of Metarhizium strains isolated in Brazil
by: Fabiana Y. Yanaka-Schäfer, et al.
Published: (2008-01-01)

Molecular Testing and Treatment Strategies in <i>RET</i>-Rearranged NSCLC Patients: Stay on Target to Look Forward
by: Maria Lucia Reale, et al.
Published: (2022-01-01)

Algorithms for computing the double cut and join distance on both gene order and intergenic sizes
by: Guillaume Fertin, et al.
Published: (2017-06-01)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update
by: Luis Mendoza
Published: (2018-07-01)

An improved approximation algorithm for the reversal and transposition distance considering gene order and intergenic sizes
by: Klairton L. Brito, et al.
Published: (2021-12-01)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
by: Yan Meng, et al.
Published: (2022-05-01)

Intergenic spacer 1 (IGS1) polymorphism map: A marker for the initial classification of cultivated Lentinula edodes strains in China
by: Xiao-xia SONG, et al.
Published: (2018-11-01)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01)

A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
by: Ting Wang, et al.
Published: (2023-02-01)

Partial Response to Crizotinib in a Lung Adenocarcinoma Patient with a Novel FBXO11 (Intergenic)-ALK (Exon 20-29) Fusion
by: He J, et al.
Published: (2023-07-01)

Comparative Mitogenomic Analysis of Heptageniid Mayflies (Insecta: Ephemeroptera): Conserved Intergenic Spacer and tRNA Gene Duplication
by: Ran Li, et al.
Published: (2021-02-01)

Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands
by: Jie Li, et al.
Published: (2019-09-01)

The calmodulin intergenic spacer as molecular target for characterization of Leishmania species
by: Aracelis Miranda, et al.
Published: (2014-01-01)

Cytomolecular analysis of ribosomal DNA evolution in a natural allotetraploid Brachypodium hybridum and its putative ancestors – dissecting complex repetitive structure of intergenic spacers
by: Natalia Borowska-Zuchowska, et al.
Published: (2016-10-01)

Comparison of Internal Transcribed Spacers and Intergenic Spacer Regions of Five Common Iranian Sheep Bursate Nematodes
by: Reza Nabavi, et al.
Published: (2014-09-01)

RET signaling pathway and RET inhibitors in human cancer
by: Angelina T. Regua, et al.
Published: (2022-07-01)

BIOINOCULANTS FOR COIR RETTING
by: A. N. Ravindranath, et al.
Published: (1995-06-01)

Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
by: Rui Wan, et al.
Published: (2024-01-01)

HOX transcript antisense intergenic RNA is differentially expressed in hypertrophic scar tissues and regulates the biological function of scar fibroblasts through sponging miR-30a-5p
by: Yong Song, et al.
Published: (2023-01-01)